Study for intra-operative imaging of prostate cancer using OTL78

Phase 1

• Conditions: Prostate cancer; Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]

• Registration Number: EUCTR2019-002393-31-NL
• Lead Sponsor: OnTarget Laboratories

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-06-25
• Last Update Posted: 25 November 2019

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

Healthy volunteers
1) Male and 18-65 years old at screening.
2) Able and willing to comply with study procedures, with signed and dated informed consent obtained before any study-related procedure is performed.
3) Agree to use an effective method of contraception for 90 days after administration.
4) A body mass index is =30 kg/m2.
5) The subject is healthy with no acute or chronic medical illnesses, has a normal physical examination, and normal vital signs findings at screening.
6) The subject’s screening 12-lead ECG and clinical laboratory test results are within normal limits, or if any are outside of normal limits they are considered clinically insignificant at the discretion of the Investigator
7) Negative screening test results for hepatitis B, hepatitis C, and human immunodeficiency virus.
8) Negative test results for drug and alcohol screening.
9) Absence of any psychological, familial, sociological or geographical condition that at the
discretion of the investigator could potentially hamper compliance with the study protocol and follow-up schedule; such conditions should be discussed with the patient during the
prescreening period.

Patients
1) Male patients > 18 years of age and older at screening
2) Able and willing to comply with study procedures, and signed and dated informed consent is
obtained before any study-related procedures are performed.
3) Known or high clinical suspicion of primary prostate cancer (Gleason score 7+)
planned for a prostatectomy
4) Known or high clinical suspicion of prostate cancer scheduled to undergo a pelvic lymph node dissection
5) The 12-lead ECG and clinical laboratory test results are within normal limits, or if any are outside of normal limits they are considered clinically insignificant at the discretion of the investigator
6) Absence of any psychological, familial, sociological or geographical condition that at the
discretion of the investigator could potentially hamper compliance with the study
protocol and follow-up schedule; such conditions should be discussed with the patient during the prescreening period.
7) Chronic or acute medical illness that in the discretion of the investigator may confound or complicate the findings in this study
8) Patients are clinically fit for surgery
9) Agree to use an effective method of contraception for 90 days after administration
10) Absence of any psychological, familial, sociological or geographical condition that at the
discretion of the investigator could potentially hamper compliance with the study protocol and follow-up schedule; such conditions should be discussed with the patient during the
prescreening period.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 24
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 24

Exclusion Criteria

Healthy volunteers
1) Female subjects
2) Known acute or chronic disease, abnormal physical examination or blood tests
3) The subject has previously been included in an OTL study.
4) Use of prescription drugs within 30 days of screening and during study participation
5) Participation in a clinical trial within 90 days of screening or more than 4 times in the previous year.
6) History of clinically significant allergies or anaphylactic reactions.
7) History of allergy to any of the components of OTL78 or excipients (see Section 3.2 IB).

Patients
1) Any condition that in the opinion of the investigators could potentially jeopardize the health status of the patient
2) History of clinically significant allergies or anaphylactic reactions.
3) History of allergy to any of the components of OTL78 or excipients (see Section 3.2 IB)
4) Impaired renal function defined as eGFR<50 ml/min/1.73m2
5) Impaired liver function defined as values greater than 3x the upper limit of normal (ULN) for ALT, AST, or 2x the upper limit of normal for total bilirubin (unless due to Gilbert Syndrome)
6) Previous participation in an OTL study

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified